Ceftolozane-tazobactam is an anti-pseudomonal cephalosporin combined with a beta-lactamase inhibitor which was licensed for the treatment of lower respiratory tract infections, urinary tract infections and intra-abdominal infections in Thailand in 2017 [21]. Here, LACTB is linked to Recurrent lower respiratory tract infections.